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I. INTRODUCTION 
Although praised for their effectiveness in managing pain, opi-
ate pain medications have also incited debate concerning their addic-
tiveness.
1
  Our legal system, charged with striking a balance between 
adequate access to pain medications and the prevention and treat-
ment of potentially corresponding drug abuse, has severely restricted 
access to addiction-assistance medications while, at the same time, has 
placed much more relaxed limitations on access to opiate pain medi-
cations.
2
  Society’s view of drug addicts may explain this imbalance, 
but addicts may use both types of medication either to feed or to treat 
their addictions. 
OxyContin is an opiate pain medication that is designed to treat 
patients with around-the-clock moderate-to-severe pain.
3
  OxyContin 
is formulated to slowly release its active ingredient, an opioid called 
oxycodone, to relieve patients’ pain.
4
  Each tablet contains a large 
quantity of oxycodone, “allow[ing] patients to take their drug less of-
ten—a distinct benefit for patients who are in chronic pain.”
5
  In 
 
 * J.D., May 2012, Seton Hall University School of Law; B.A., 2004, American Uni-
versity; M.A., 2005, Rutgers University.  The author wishes to thank the members of 
the Seton Hall Law Review and Kate Greenwood for their help in drafting this Com-
ment.  The author would also like to thank her first friend for motivating her to 
bring this issue to light. 
 1 See U.S. DEP’T OF HEALTH & HUMAN SERVS., SUBSTANCE ABUSE TREATMENT 
ADVISORY, PUB. NO. (SMA) 06-4138, OXYCONTIN: PRESCRIPTION DRUG ABUSE-2006 
REVISION  2 (2006), available at http://kap.samhsa.gov/products/brochures/ 
advisory/pdfs/Oxycontin-Advisory.pdf. 
 2 See infra Part III.A–C. 
 3 OxyContin—Questions and Answers, U.S. FOOD & DRUG ADMIN. (Apr. 5, 2010), 
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatient
sandProviders/ucm207196.htm. [hereinafter OxyContin—Questions and Answers].   
 4 Id. 
 5 Id.  
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2009, physicians wrote 6.2 million prescriptions for OxyContin, and 
its retail sales reached three billion dollars.
6
 
When a user breaks, cuts, or chews OxyContin pills, however, 
their time-release property is destroyed, and the user immediately re-
ceives the full dose of oxycodone.
7
  In 2009, 584,000 people age 
twelve or older became “new nonmedical users” of OxyContin.
8
  A 
2008 study found that 2.1% of eighth graders, 3.6% of tenth graders, 
and 4.7% of twelfth graders had abused OxyContin for nonmedical 
purposes at least once in the year prior to being surveyed.
9
  Between 
2004 and 2008, emergency room visits for oxycodone products in-
creased 152%.
10
  Among persons age twelve and older, only marijuana 
use is a more prevalent form of drug abuse than that of pain reliev-
ers.
11
 
The Food and Drug Administration (FDA) has approved three 
drugs to assist patients in combating opiate addictions: methadone, 
buprenorphine (in two formulations, Subutex and Suboxone), and 
naltrexone.
12
  Naltrexone is also available in an injectable, time-
release formula called Vivitrol.
13
  All three drugs treat addiction to 
 
 6 U.S. FOOD & DRUG ADMIN., ANNUAL U.S. OXYCONTIN PRESCRIPTIONS (MILLIONS) 
(2010), available at http://www.fda.gov/downloads/AdvisoryCommittees/ 
CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCom
mittee/UCM220954.pdf. 
 7 OxyContin—Questions and Answers, supra note 3. 
 8 U.S. DEP’T OF HEALTH & HUMAN SERVS., PUB. NO. SMA 10-4586, RESULTS FROM 
THE 2009 NATIONAL SURVEY ON DRUG USE AND HEALTH: VOLUME I. SUMMARY OF 
NATIONAL FINDINGS 58 (2010), available at http://www.oas.samhsa.gov/NSDUH/ 
2k9NSDUH/2k9ResultsP.pdf. 
 9 NAT’L INSTS. OF HEALTH, PRESCRIPTION AND OVER-THE-COUNTER MEDICATIONS 7 
(2009), available at https://www.drugabuse.gov/sites/default/files/painmed09.pdf. 
 10 SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., THE DAWN REPORT: 
TRENDS IN EMERGENCY DEPARTMENT VISITS INVOLVING NONMEDICAL USE OF NARCOTIC 
PAIN RELIEVERS 1 (2010), available at http://oas.samhsa.gov/2k10/DAWN016/ 
OpioidEdHTML.pdf. 
 11 Id.  
 12 PHYSICIANS & LAWYERS FOR NAT’L DRUG POLICY, ALCOHOL AND OTHER DRUG 
PROBLEMS: A PUBLIC HEALTH AND PUBLIC SAFETY PRIORITY 40–41(2008), available at 
http://www1.spa.american.edu/justice/ 
document.php?ID=2434; see also Gregory B. Collins & Mark S. McAllister, Buprenor-
phine Maintenance: A New Treatment for Opioid Dependence, 74 CLEVELAND CLINIC J. MED. 
514, 514–16 (2007) (describing use of buprenorphine and methadone in treating 
opioid dependence); Patrick G. O’Connor & David A. Fiellin, Pharmacologic Treatment 
of Heroin-Dependent Patients, 133 ANNALS INTERNAL MED. 40, 44–47 (2000) (describing 
use of naltrexone in treating opioid dependence). 
 13 Caleb Hellerman, FDA OKs Drug to Fight Opiate Addiction, CNN HEALTH  CHART 
BLOG (Oct. 12, 2010, 6:53 PM), http://pagingdrgupta.blogs.cnn.com/2010/ 
10/12/fda-oks-drug-to-fight-opiate-addiction/?iref=allsearch. 
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opiates, including heroin and prescription medications like 
OxyContin.
14
  Methadone is a long-lasting, synthetic opioid medica-
tion that prevents withdrawal, blocks the euphoric effects of heroin 
and prescription opiates, and decreases cravings.
15
  Methadone is an 
opioid agonist,
16
 which means that it mimics the effects of the abused 
opiate.
17
  “Buprenorphine is an opioid partial agonist,” which means 
that it can produce the effects of an agonist (i.e., euphoria and res-
piratory depression), but its maximum agonistic effect is much less 
than that of a full agonist like methadone.
18
  Buprenorphine also re-
duces cravings, blocks the effect of heroin and other opiates, reduces 
adverse symptoms associated with withdrawal, and has a long dura-
tion of action.
19
  Unlike methadone or buprenorphine, naltrexone is 
an opioid antagonist, which means that it blocks receptors in the 
brain to prevent users from obtaining the euphoric effects of heroin 
and other opiates.
20
  By depriving the patient of the abused opiate’s 
effects, naltrexone works to break the habit of opiate addiction.
21
 
In 2006, recognizing the need to combat opiate addiction, the 
World Health Organization (WHO) added methadone and bupren-
orphine to its Fourteenth Model List of Essential Medicines.
22
  Alt-
hough physicians in the United Kingdom, France, and Australia have 
utilized addiction-assistance medications as an effective tool to treat 
opiate dependence,
23
 the same has not been true in the United 
 
 14 PHYSICIANS & LAWYERS FOR NAT’L DRUG POLICY, supra note 12, at 39. 
 15 David A. Fiellin & Patrick G. O’Connor, New Federal Initiatives to Enhance the 
Medical Treatment of Opioid Dependence, 137 ANNALS INTERNAL MED. 688, 688 (2002); 
O’Connor & Fiellin, supra note 12, at 45–46; NAT’L INSTS. OF HEALTH, NIH PUB. NO. 
99-4180, PRINCIPLES OF DRUG ADDICTION TREATMENT: A RESEARCH-BASED GUIDE 37 (2d. 
ed. 2009), available at https://www.drugabuse.gov/sites/default/files/podat_0.pdf. 
 16 See U.S. DEP’T OF HEALTH & HUMAN SERVS.,  THE DASIS REPORT: PLANNED 
METHADONE TREATMENT FOR HEROIN ADMISSIONS 1 (2003), available at 
http://www.samhsa.gov/data/2k3/MethadoneHtx/methadoneHtx.pdf. 
 17 GOODMAN AND GILMAN’S MANUAL OF PHARMACOLOGY AND THERAPEUTICS 14 
(Laurence Brunton, et al. eds., 2008). 
 18 About Buprenorphine Therapy, CSAT BUPRENORPHINE INFO. CENTER, 
http://buprenorphine.samhsa.gov/about.html (last visited March 12, 2012). 
 19 Hendree E. Jones, Practical Considerations for the Clinical Use of Buprenorphine, 
SCI. & PRAC. PERSP., Aug. 2004, at 4, 4–5, available at http://www.naabt.org/ 
documents/Practical_Conciderations%20.pdf. 
 20 PHYSICIANS & LAWYERS FOR NAT’L DRUG POLICY, supra note 12, at 41. 
 21 NAT’L INST. OF HEALTH, supra note 15, at 40. 
 22 WORLD HEALTH ORG., WHO MODEL LIST OF ESSENTIAL MEDICINES 21 (14th ed. 
2005), available at http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf. 
 23 Fiellin & O’Connor, supra note 15, at 691 (describing opioid agonist mainte-
nance treatment in the United Kingdom, Australia, and France). 
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States.
24
  In the United States, an imbalanced legal structure permits 
the wide dissemination of highly addictive pain medications, but lim-
its access to addiction-assistance medications.  This imbalance ex-
plains the underutilization of addiction-assistance medications in the 
United States. 
This Comment argues that the incongruent legal treatment of 
addiction-assistance medications in comparison to opiate pain medi-
cations is a flawed system because it increases access to opiates while 
limiting access to addiction assistance.  This Comment will use 
OxyContin as an illustration of all opiate pain medications because it 
is so widely abused and because of the controversy surrounding the 
product’s design.
25
  Part II will explain the legal framework under 
which all medications fall, highlighting in particular the statutes that 
are applicable to this analysis.  Part III will discuss the statutes and 
regulations that apply to OxyContin, methadone, and buprenor-
phine, focusing on important differences and incongruities between 
the two legal structures.  Notably, both methadone and buprenor-
phine are regulated more heavily than OxyContin despite the fact 
that methadone is in the same controlled substance schedule as 
OxyContin and buprenorphine is in a less restrictive controlled sub-
stance schedule.  Part IV will recommend changes that will amelio-
rate the disparate treatment of these medications, addressing the 
supply and demand sides of this problem and highlighting the Wash-
ington state model, which requires physicians to refer patients to pain 
specialists once their pain requires a certain dosage of an opiate pain 
reliever, as an example.  This Comment does not advocate restricting 
access to pain medications for those in legitimate need, but it does 
question the logic of permitting the wide dissemination of drugs like 
OxyContin and, simultaneously, severely restricting access to metha-
done and buprenorphine. 
 
 24 James L. Nolan, Jr., Harm Reduction and the American Difference: Drug Treatment 
and Problem-Solving Courts in Comparative Perspective, 13 J. HEALTH CARE L. & POL’Y 31, 
36–37 (2010). 
 25 Cf. Jennifer Corbett Dooren, FDA Approves Reformulated OxyContin, WALL ST. J. 
(Apr. 6, 2010),  http://online.wsj.com/article/ 
SB10001424052702304620304575166391268139192.html (reporting that the FDA 
approved a reformulated version of OxyContin on April 5, 2010, which is supposed 
to be more tamper resistant). 
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II.  THE REGULATORY FRAMEWORK FOR PRESCRIPTION MEDICATIONS 
Federal and state laws make up the legal framework for all medi-
cations.
26
  The two pertinent federal statutes are the Food, Drug and 
Cosmetic Act (FDCA)
27
 and the Controlled Substances Act (CSA).
28
  
State controls on physician licensing also contribute to the legal 
structure.
29
  In addition, many states have adopted the Uniform Con-
trolled Substances Act (UCSA)
30
 and/or a law, like the Pain Relief 
Act,
31
 guarding the right to pain medication.
32
 
In 1938, Congress passed the FDCA.
33
  The FDA administers the 
FDCA,
34
 and it is responsible for determining the safe and effective 
use of prescription medications.
35
  Drug research, testing, and clinical 
trials make up the drug approval process.
36
  The process begins with 
the drug manufacturer conducting various laboratory and animal 
tests.
37
  Next, the manufacturer conducts testing with humans.
38
  After 
the tests, the manufacturer submits a New Drug Application, which 
includes the test results, to the Secretary of Health and Human Ser-
vices.
39
  The FDA’s physicians and scientists review the application.
40
  
 
 26 David E. Joranson & Aaron Gilson, Controlled Substances, Medical Practice, and the 
Law, in PSYCHIATRIC PRACTICE UNDER FIRE: THE INFLUENCE OF GOVERNMENT, THE MEDIA 
AND SPECIAL INTERESTS ON SOMATIC THERAPIES 173, 175–90 (Harold I. Schwartz ed., 
1994). 
 27 21 U.S.C §§ 301–399d (2006). 
 28 Id. §§ 801–971. 
 29 See generally Becoming a Physician: Medical Licensure, AM. MED. ASSOC., 
http://www.ama-assn.org/ama/pub/education-careers/becoming-
physician/medical-licensure.shtml (last updated April 17, 2011). 
 30 UNIF. CONTROLLED SUBSTANCES ACT (1994). 
 31 The Pain Relief Act, 24 J. L. MED. & ETHICS 317(1996).  
 32 See generally Database of State Statutes, Regulations, and Other Official Governmental 
Policies, PAIN & POL’Y STUD. GROUP, http://www.painpolicy.wisc.edu/matrix.htm (last 
updated Dec. 7, 2011) (containing a matrix of all state statutes, regulations, and 
guidelines concerning controlled substances and pain)[hereinafter Database of State 
Statutes]. 
 33 Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as amended in scattered sec-
tions of 21 U.S.C.). 
 34 21 U.S.C. § 301 (2006). 
 35 See id. § 355(a).   
 36 Kimani Paul-Emile, Making Sense of Drug Regulation: A Theory for Drug Control Pol-
icy, 19 CORNELL J.L. & PUB. POL’Y 691, 698 (2010).   
 37 What Is the Approval Process for a New Prescription Drug?, U.S. FOOD & DRUG 
ADMIN., http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194949.htm (last 
visited Jan. 27, 2012) [hereinafter What Is the Approval Process for a New Prescription 
Drug?]. 
 38 Id. 
 39 Id.; § 355(b). 
 40 What Is the Approval Process for a New Prescription Drug?, supra note 37. 
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If they determine that the drug’s benefits outweigh its known risks 
and that the drug can be manufactured in a way that ensures a quality 
product, then the FDA approves the drug and the manufacturer can 
market it in the United States.
41
  As of 2007, the FDA is authorized to 
require an applicant to adopt a Risk Evaluation and Mitigation Strat-
egy (REMS) if the FDA determines that such a strategy is necessary to 
ensure that the drug’s benefits outweigh its risks.
42
 
Congress passed the Comprehensive Drug Abuse Prevention and 
Control Act of 1970 as the first universal drug legislation.
43
  Title II of 
the Act is the CSA,
44
 which classifies controlled substances into five 
schedules.
45
  Schedule placement depends on a controlled sub-
stance’s legitimate medical value, the risk for abuse, and its potential 
addictiveness.
46
  A controlled substance’s schedule dictates the degree 
of restriction with which the FDA treats each substance.
47
  Schedule I 
controlled substances, like heroin and lysergic acid diethylamide 
(LSD),
48
 are strictly prohibited, while Schedule V controlled sub-
stances are the least restricted and include commonly used painkill-
ers like Codeine.
49
 
The Drug Enforcement Administration (DEA), part of the Unit-
ed States Department of Justice, administers the CSA.
50
  The DEA 
must consult with the FDA before scheduling a drug as a controlled 
substance.
51
  Because the FDA’s recommendations on the scientific 
and medical value of a drug are binding on the DEA, the DEA cannot 
schedule a drug if the FDA recommends otherwise.
52
 
The DEA may establish total quantity and production quotas for 
Schedule I and Schedule II drugs.
53
  When establishing quotas, the 
 
 41 Id. 
 42 21 U.S.C. § 355-1(a) (2006). 
 43 1970-1975, U.S. DRUG ENFORCEMENT ADMIN., http://www.justice.gov/dea/ 
pubs/history/deahistory_01.htm (last visited Nov. 9, 2011). 
 44 21 U.S.C. §§ 801–971 (2006). 
 45 § 812(a). 
 46 Paul-Emile, supra note 36, at 698; see § 812(b). 
 47 See § 812(b); Dispensing of Controlled Substances to Residents at Long Term 
Care Facilities, 75 Fed. Reg. 37,463, 37,464 (June 29, 2010). 
 48 § 812(c). 
 49 See Dispensing of Controlled Substances to Residents at Long Term Care Facil-
ities, 75 Fed. Reg. 37,464 (June 29, 2010). 
 50 Exec. Order No. 11,727, 38 Fed. Reg. 18,357 (July 6, 1973). 
 51 PETER BARTON HUTT ET AL., FOOD AND DRUG LAW: CASES AND MATERIALS 719 (3d 
ed. 2007). 
 52 21 U.S.C. § 811(b) (2006). 
 53 Id. § 826; Western Fher Laboratories v. Levi, 529 F.2d 325, 327 (1st Cir. 1976).   
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Attorney General considers, but is not limited to, the disposal rates of 
the manufacturer, national trends of disposal, inventory and produc-
tion cycles, the drug’s stability, the availability of raw materials used in 
the manufacture of the drug, and emergencies, such as strikes and 
fires.
54
 
Anyone who wishes to dispense controlled substances, such as a 
physician, a hospital, or a pharmacy, must register with the DEA.
55
  To 
be eligible to obtain a registration, a practitioner must be licensed or 
otherwise authorized to dispense controlled substances under the 
laws of the state in which he or she practices.
56
  DEA registration and 
the CSA permit the practitioner to dispense controlled substances to 
the extent that they are authorized under the law.
57
 
The CSA also requires registrants to maintain a current and 
complete record of each controlled substance that they have dis-
pensed.
58
  The drug’s schedule determines whether the physician may 
provide an oral prescription to a pharmacist or whether a written 
prescription is required.
59
  If a practitioner violates any requirements 
under the CSA or if his or her license has been suspended, revoked 
or denied, the Attorney General can take legal action to suspend or 
revoke the practitioner’s DEA registration.
60
 
In addition to the federal statutory structure for medications, 
state laws and licensing requirements create the legal framework for 
prescribers.
61
  In general, each state has a medical board charged with 
setting physician, hospital, and pharmacy licensing requirements and 
with evaluating applicants to ensure that they meet those require-
ments.
62
  Licensure requirements vary from state to state, but they 
generally include meeting certain education and training require-
ments, passing an examination demonstrating competency to prac-
tice medicine, and a background check to verify professional compe-
tence, ethics, and character.
63
 
 
 54 § 826(c). 
 55 Id. § 822(a); 21 C.F.R. § 1301.11 (2012). 
 56 Id. § 823(f) 
 57 § 822(b). 
 58 Id. § 827(a). 
 59 See id. § 829. 
 60 Id. § 824. 
 61 Joranson & Gilson, supra note 26, at 175. 
 62 Dispensing of Controlled Substances to Residents at Long Term Care Facili-
ties, 75 Fed. Reg. 37,467 (June 29, 2010). 
 63 Id. 
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Many states have adopted, in whole or in part, two model stat-
utes in the drug-regulation area—the Uniform Controlled Substances 
Act (UCSA) and the Pain Relief Act.
64
  The National Conference of 
Commissioners on Uniform State Statutes drafted the UCSA in 1994 
to maintain uniformity between the laws of the states and the federal 
government and to provide guidance on how the federal and state 
laws should interact for the best use of government resources.
65
  The 
UCSA also “provides law enforcement tools to improve investigative 
efforts and provides for education and training programs relating to 
the drug abuse problem.”
66
  The UCSA scheduling is identical to that 
contained in the CSA.
67
  The UCSA provides states with discretion, 
including setting penalties for violations of the Act; requiring manu-
facturers, distributors, and dispensers of controlled substances to reg-
ister with the appropriate state authority; setting the parameters for 
obtaining registration; and setting the grounds for suspension or rev-
ocation of registration.
68
 
The Pain Relief Act is another model statute.
69
  Its goals are to 
protect physicians who prescribe pain medications from prosecution 
or disciplinary or licensing actions and to protect patients’ access to 
pain medication.
70
  The Act does not protect practitioners who fail to 
maintain required records, write false prescriptions, or illegally divert 
medications for non-medical uses.
71
  The Act refers to addiction and 
chemical dependency once, but it does so in the context of protect-
ing access rather than expressing concern for abuse.
72
  The Act pro-
vides that all patients are entitled to the same access to pain relief 
medication “regardless of the patient’s prior or current chemical de-
pendency or addiction.”
73
  The drafters, however, afford states the 
discretion to appoint an appropriate state body to develop standards 
and procedures “for the application of this Act to the care and treat-
ment of chemically dependent individuals.”
74
 
 
 64 See Database of State Statutes, supra note 32. 
 65 UNIF. CONTROLLED SUBSTANCES ACT Prefatory Note, at 1 (1994). 
 66 Id. Prefatory Note, at 2. 
 67 See id. §§ 201–212. 
 68 Id. §§ 301–305, 401. 
 69 The Pain Relief Act, 24 J. L. MED. & ETHICS 317(1996). 
 70 See id. at 318. 
 71 Id. (see Sec. 4.a. –d.). 
 72 Id. (see Sec. 3.3). 
 73 Id. 
 74 Id. 
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III.  COMPARING OXYCONTIN’S REGULATORY FRAMEWORK WITH THAT 
FOR METHADONE AND BUPRENORPHINE 
Federal regulations of methadone and buprenorphine are much 
more stringent than those of OxyContin.
75
  Although the DEA has 
scheduled methadone and OxyContin identically, and despite the 
DEA scheduling buprenorphine in a less restrictive schedule than 
OxyContin, the addiction-assistance medications are subject to dos-
age restrictions, patient limitations, and special physician registration 
requirements that do not apply to OxyContin and its prescribers.
76
 
A. OxyContin 
The FDA initially approved OxyContin on December 12, 1995.
77
  
In 2010, the FDA approved a new formulation of OxyContin.
78
  The 
new pill was designed to resist efforts to circumvent its controlled-
release property.
79
  The effectiveness of the new design remains un-
known.
80
  Like methadone, OxyContin is a Schedule II drug under 
the CSA.
81
  Although Schedule II drugs have a high potential for 
abuse, they also have a “currently accepted medical use in treatment 
in the United States or a currently accepted medical use with severe 
restrictions.”
82
  Severe psychological or physical dependence may re-
sult from the abuse of a Schedule II controlled substance.
83
  The CSA 
provides that, except in emergency situations, a pharmacy may only 
dispense a Schedule II controlled substance pursuant to a practition-
er-signed written prescription.
84
 
 
 75 See infra Part III.A–C. 
 76 See infra Part III.A–C. 
 77 OxyContin: Balancing Risks and Benefits: Hearing Before the S. Comm. on Health, 
Educ., Labor and Pensions, 107th Cong. 14 (2002) (statement of John K. Jenkins, Dir., 
Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Ad-
min.) [hereinafter Jenkins]. 
 78 See Letter from Bob A. Rappaport, Dir. Div. of Anesthesia and Analgesia Prod-
ucts, Center for Drug Evaluation and Research, to Craig Landau, Chief Med. Officer 
& Vice President, Clinical, Med. & Reg. Affairs, Purdue Pharma, (Apr. 5, 2010), 
available at http://www.accessdata.fda.gov/ 
drugsatfda_docs/appletter/2010/022272s000ltr.pdf. 
 79 See id.  
 80 See New Tamper-Resistant OxyContin Tablets to be Released August 2010, NAT’L ASS’N 
BOARDS PHARMACY (Aug. 19, 2010, 11:04 AM), http://www.nabp.net/news/new-
tamper-resistant-oxycontin-tablets-to-be-released-august-2010/. 
 81 Jenkins, supra note 77. 
 82 21 U.S.C. § 812(b)(2)(A)–(C) (2006).   
 83 § 812(b)(2)(C). 
 84 Id. § 829(a).   
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In contrast to the addiction-assistance medications discussed be-
low,
85
 prescribers of OxyContin must comply with only one regulatory 
limitation.
86
  It is a supply limitation, and an exception in the regula-
tion loosens it.
87
  Although the CSA prohibits the refill of prescrip-
tions for Schedule II controlled substances,
88
 the DEA has issued a 
regulation that allows practitioners to issue multiple prescriptions at a 
time, which means that a physician can provide a patient with up to 
three thirty-day prescriptions of OxyContin at once.
89
  Despite 
OxyContin’s and methadone’s identical classification, this exception 
does not apply to methadone.
90
 
Although methadone and OxyContin are both Schedule II sub-
stances and although buprenorphine is in a less restrictive classifica-
tion than both, only the addiction-assistance medications require a 
practitioner to meet a special DEA registration requirement.
91
  There-
fore, any practitioner who has registered with the DEA can prescribe 
OxyContin, and no practitioner is under any obligation to meet any 
training requirements to prescribe OxyContin. 
The OxyContin REMS requires that the manufacturer send 
training materials, including information on patient selection, dos-
ing, risks, and addiction, to healthcare professionals.
92
  The training 
packet includes an OxyContin Education Confirmation Form.
93
  The 
manufacturer maintains a list of the prescribers who submit the 
form.
94
  While a prescriber’s signature on the form confirms that he 
or she “read the REMS Education Materials for OxyContin
 
and un-
derstand[s] the major risks associated with OxyContin and how to 
appropriately select and educate patients to whom OxyContin is pre-
scribed,” failure to complete the form does not affect a physician’s 
ability to prescribe the drug.
95
  The OxyContin REMS also requires 
the drug manufacturer to provide prescribing information and a 
medication guide with each bottle of the drug and imposes labeling 
 
 85 See infra Part III.B–C. 
 86 See 21 C.F.R. § 1306.12 (2012). 
 87 See id. 
 88 § 829(a).  
 89 § 1306.12. 
 90 See id. 
 91 21 U.S.C. § 823(g)(1) (2006). 
 92 PURDUE PHARMA, OXYCONTIN RISK EVALUATION MITIGATION STRATEGY 2 (2010), 
http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformati
onforPatientsandProviders/UCM220990.pdf. 
 93 Id. at 3. 
 94 Id. 
 95 Id. at 35. 
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requirements.
96
  The REMS also advises prescribing physicians to in-
form patients to flush unused tablets down the toilet.
97
  Patients also 
receive this information in the eight-page medication guide.
98
  Ac-
cordingly, unlike addiction-assistance medications, any physician can 
prescribe OxyContin without meeting any training or DEA registra-
tion requirements and without ever certifying that he or she read the 
training materials that the REMS obligates the manufacturer to pro-
vide. 
The only other limitation placed on OxyContin relates to the 
DEA’s quota powers for Schedule I and II controlled substances.
99
  
Oxycodone is the opiate pain reliever that OxyContin contains.
100
  
Until 2011, the DEA had increased the quota for oxycodone every 
year since 2002
101
 with the exception of 2008, when the quota re-
mained unchanged from 2007.
102
  In 2010, the quota for oxycodone 
available for sale was 105,500,000 grams.
103
  In 2002, the quota for ox-
ycodone available for sale was 34,482,000 grams, which means that 
over that eight-year period, the DEA permitted a 206% increase in 
the oxycodone quota.
104
  The DEA decreased the quota to 98,000,000 
grams in 2011.
105
  OxyContin is available in seven dosage strengths, 
ranging from ten milligram to eighty milligram tablets.
106
  Although 
oxycodone is used in other medications, if one assumes, for illustra-
tive purposes, that OxyContin was the only medication manufactured 
from oxycodone, the 2010 quota would permit the production of be-
tween 15,050,000,000 (for ten milligram tablets) and 1,881,250,000 
 
 96 Id. at 1–2; see also PURDUE PHARMA, MEDICATION GUIDE (2010), 
http://www.fda.gov/downloads/Drugs/DrugSafety/UCM208530.pdf. 
 97 PURDUE PHARMA, supra note 96. 
 98 Id.  
 99 See 21 C.F.R. § 1315.30 (2012). 
 100 OxyContin—Questions and Answers, supra note 3. 
 101 See Federal Register Notices, OFFICE DIVERSION CONTROL, 
http://www.deadiversion.usdoj.gov/fed_regs/index.html (last visited, Jan. 26, 
2012)(listing the quotas for each year under a separate link). 
 102 Compare Controlled Substances: Final Revised Aggregate Production Quotas 
for 2007, 72 Fed. Reg. 48,616, 48,618 (Aug. 24, 2007), with  Controlled Substances: 
Final Revised Aggregate Production Quotas for 2008, 73 Fed. Reg. 66,939, 66,941 
(Nov. 12, 2008). 
 103 Controlled Substances: Final Revised Aggregate Production Quotas for 2010, 
75 Fed. Reg. 55,828, 55,830 (Sept. 14, 2010).  
 104 Controlled Substances: Final Revised Aggregate Production Quotas for 2002, 
67 Fed. Reg. 59,313, 59,315 (Sept. 20, 2002). 
 105 Controlled Substances: Final Revised Aggregate Production Quotas for 2011, 
76 Fed. Reg. 77,016, 77,019 (Dec. 9, 2011). 
 106 PURDUE PHARMA, supra note 92, at 29. 
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(for eighty milligram tablets) tablets of OxyContin.  Although the 
DEA has the power to limit OxyContin production through its quota 
authority, the DEA has dramatically increased the availability of ox-
ycodone over the last eight years.  While this may be warranted for le-
gitimate users, the increase remains in stark contrast to the limited 
availability of addiction-assistance medications.
107
  Additionally, while 
the rate of marijuana dependence or abuse has remained steady over 
the last eight years, the number of people suffering from pain-
reliever dependence or abuse has increased from 1.5 million to 1.9 
million over the same period of time.
108
 
B. Methadone 
The FDA approved methadone in late 1972 to treat opiate addic-
tion.
109
  “Methadone is to an addict what insulin is to a diabetic, for 
both drugs enable an otherwise ill individual to function as a healthy, 
normal human being contributing his part to society.”
110
  Although 
not a cure for opiate addiction, when used as a short-term therapy or 
in a “long-term maintenance treatment program,”
111
 methadone “im-
prove[s] treatment retention, decreas[es] relapse, and ameliorat[es] 
the other social, legal, and medical problems often associated with 
illicit drug misuse.”
112
 
Despite the identical controlled substance classification of 
OxyContin and methadone,
113
  the regulatory and statutory treatment 
of methadone is far more restrictive than OxyContin’s, particularly in 
regards to patients’ access.
114
  The patients each drug is designed to 
serve—drug addicts versus pain sufferers—may explain this disparity.  
In light of the rates of OxyContin abuse,
115
 however, some portion of 
 
 107 See infra Part.III.B.–C. 
 108 U.S. DEP’T OF HEALTH & HUMAN SERVS., supra note 8, at 6. 
 109 INST. OF MED., FEDERAL REGULATION OF METHADONE TREATMENT 1 (Richard A. 
Rettig & Adam Yarmolinsky eds.,1995). 
 110 Andrew G. Bucaro & Mary Williams Cazalas, Methadone: Treatment and Control of 
Narcotic Addiction, 44 TUL. L. REV. 14, 31 (1969). 
 111 21 U.S.C. § 802(29) (2006) (“The term ‘maintenance treatment’ means the 
dispensing, for a period in excess of twenty-one days, of a narcotic drug in the treat-
ment of an individual for dependence upon heroin or other morphine-like drugs.”). 
 112 Richard C. Boldt, Introduction: Obstacles to the Development and Use of Pharma-
cotherapies for Addiction, 13 J. HEALTH CARE L. & POL’Y 1, 3 (2010) (citing Karen L. Sees 
et al., Methadone Maintenance vs 180-Day Psychosocially Enriched Detoxification for Treat-
ment of Opioid Dependence: A Randomized Controlled Trial, 283 JAMA 1303, 1309 (2000)). 
 113 See 21 U.S.C. § 812(c) (2006).   
 114 See infra Part.III.B.–C. 
 115 See supra text accompanying notes 7–11. 
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OxyContin prescriptions are, in fact, provided to drug addicts.  Ac-
cordingly, a distinction based on patient needs alone fails to fully jus-
tify the radical disparities. 
The Narcotic Addiction Treatment Act of 1974 and the Drug 
Addiction Treatment Act of 2000 amended the CSA, updating ap-
proval and licensing procedures for practitioners who treat opiate 
addiction with medication.
116
  On January 21, 2001, the Substance 
Abuse and Mental Health Services Administration (SAMHSA) of the 
Department of Health and Human Services promulgated regulations 
concerning the treatment of opiate dependence with addiction-
assistance medications.
117
  The regulations define the registration re-
quirements for practitioners and the accreditation and certification-
based system for facilities that dispense methadone, referred to as 
Opioid Treatment Programs (OTPs), which SAMHSA oversees.
118
  
The Administrator of SAMHSA has delegated some oversight respon-
sibilities to its Center for Substance Abuse Treatment (CSAT) and, 
within CSAT, to the Division of Pharmacologic Therapies.
119
  The 
regulations did not disturb the states’ authority to regulate OTPs.
120
  
Accordingly, a tripartite system of oversight between the states, 
SAMHSA, and the DEA remained in place after the amendments.
121
 
1. Opioid Treatment Programs 
Unlike OxyContin, which is available from any doctor’s office, 
methadone is only available from OTPs, which are subject to heavy 
federal regulation and frequent local zoning controversies.
122
  The 
process to qualify as an OTP consists of two parts—accreditation and 
certification.
123
  Accreditation is a peer-review process.
124
  Reviewers 
evaluate the OTP’s pending application pursuant to SAMHSA’s OTP 
 
 116 JOSEPH T. RANNAZZISI & MARK W. CAVERLY, DRUG ENFORCEMENT ADMIN., 
PRACTITIONER’S MANUAL 23 (2006), available at 
http://www.deadiversion.usdoj.gov/pubs/manuals/pract/pract_manual012508.pdf; 
see Narcotic Addiction Treatment Act of 1974, Pub. L. No. 93-281, 88 Stat. 124; 21 
U.S.C. § 823(g) (2006). 
 117 42 C.F.R. §§ 8.1–8.34 (2011). 
 118 § 8.11. 
 119 Opioid Treatment Regulation, SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., 
http://www.dpt.samhsa.gov/regulations/regindex.aspx  (last visited Mar. 12, 2012) 
[hereinafter Opioid Treatment Regulation]; see also § 8.11(f)(2) (providing discretion to 
certain entities). 
 120 See § 8.11(f). 
 121 See § 8.11(f)(2). 
 122 PHYSICIANS & LAWYERS FOR NAT’L DRUG POLICY, supra note 12, at 40. 
 123 42 C.F.R. § 8.4 (2011). 
 124 Id. 
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standards and visit the facility to verify that it meets accreditation re-
quirements.
125
  After accreditation, “SAMHSA uses the accreditation 
results along with other data to determine whether the program is 
qualified to carry out treatment under the standards in the regula-
tions.”
126
  SAMHSA then certifies the programs that qualify, at which 
time these programs can dispense methadone.
127
 
In addition to the federally-required accreditation and certifica-
tion process, an OTP must comply with local zoning restrictions.
128
  
Zoning is an exercise of the state’s police power.
129
  A relatively recent 
line of cases in Pennsylvania illustrates the tension between local zon-
ing initiatives and anti-discrimination laws.
130
  In New Directions Treat-
ment Services v. City of Reading, the Third Circuit invalidated a zoning 
statute that provided specific limitations on methadone facilities, 
finding that the statute violated the Americans with Disabilities Act 
(ADA) and the Rehabilitation Act.
131
  The Pennsylvania statute
132
 at 
issue in New Directions restricted  the location of the methadone facili-
ty, specifically its proximity to residential housing, schools, parks, 
playgrounds, churches or other establishments of regular religious 
worship, and child-care facilities.
133
  The statute also provided that a 
local governing body could opt out of the proximity restriction by 
majority vote, allowing a methadone facility to operate closer to a re-
stricted building than provided in the statute.
134
  The City of Reading 
(the “City”) did not opt out of the proximity requirements and de-
nied a permit to New Directions Treatment Services (“New Direc-
tions”), a methadone treatment facility.
135
  New Directions appealed 
the denial.
136
  The district court granted the City’s motion for sum-
mary judgment.
137
 
 
 125 Id. 
 126 Opioid Treatment Regulation, supra note 119. 
 127 Id. 
 128 See New Directions Treatment Servs. v. City of Reading, 490 F.3d 293, 298 (3d 
Cir. 2007). 
 129 See Village of Euclid v. Ambler Realty Co., 272 U.S. 365, 387 (1926). 
 130 See New Directions, 490 F.3d 293; see also Freedom Healthcare Servs. v. Zoning 
Hearing Bd. of New Castle, 983 A.2d 1286 (Pa. Commw. Ct. 2009). 
 131 New Directions, 490 F.3d 293. 
 132 53 PA. CONS. STAT ANN. § 10621 (West 1999). 
 133 New Directions, 490 F.3d at 299. 
 134 Id. 
 135 Id. at 299. 
 136 Id. at 300. 
 137 Id. 
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New Directions then appealed to the Third Circuit, which held 
that providing local governments the ability to waive the proximity 
restrictions did not mitigate the fact that the law singled out metha-
done facilities—and therefore methadone patients—and that this 
rendered the statute facially discriminatory under the ADA and the 
Rehabilitation Act.
138
  If, however, the methadone facility posed a sig-
nificant risk to the population, the ADA and the Rehabilitation Act 
would not prohibit the zoning restrictions.
139
  Relying on objective ev-
idence, like links between crime rates and methadone clinics, the 
United States Court of Appeals for the Third Circuit found no evi-
dence to support the safety concerns that the City and its residents 
raised; the court found that the denial more closely resembled “dep-
rivations based on prejudice, stereotypes, or unfounded fear.”
140
  Ac-
cordingly, the significant risk doctrine did not validate the zoning 
statute.
141
 
The Third Circuit also evaluated whether the City violated the 
Fourteenth Amendment’s guarantee of equal protection in its appli-
cation of the statute.
142
  The court remanded the claim, instructing 
the district court to apply the rational basis test and to determine: (1) 
whether the issues raised that were unrelated to the nature of the fa-
cility or its clientele, such as loitering, noise, or parking, differentiat-
ed this facility from other permitted uses, and (2) whether such a dis-
tinction would permit denying the permit or whether the purported 
legitimate reasons for the denial were pretextual.
143
 
Two years later in Freedom Healthcare Services v. Zoning Hearing 
Board of the City of New Castle, the Pennsylvania Commonwealth Court 
relied on New Directions to find that a zoning board had improperly 
denied a zoning permit to a methadone facility.
144
  Here, the board 
based the denial on the lack of parking; the danger to the health, 
safety, and welfare of the neighborhood that the facility would pre-
sent because of the applicant’s “noticeable inexperience” in running 
a methadone facility; the increase in traffic; and the presence of chil-
 
 138 Id. at 305. 
 139 New Directions, 490 F.3d at 305. 
 140 Id. at 307 (citing School Bd. of Nassau Cnty. v. Arline, 480 U.S. 273, 287 
(1987)). 
 141 Id. 
 142 Id. at 310. 
 143 Id. at 312. 
 144 Freedom Healthcare Servs. v. Zoning Hearing Bd. of New Castle, 983 A.2d 
1286 (Pa. Commw. Ct. 2009). 
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dren in the area of the facility.
145
  Freedom Healthcare Services ar-
gued that the board improperly applied the zoning ordinance and 
that the zoning permit application met all parking requirements.
146
  
The board asserted that Freedom Healthcare Services had the bur-
den of producing sufficient evidence to demonstrate that it would 
not harm the health and safety of the community based on the facili-
ty’s hours, patients, and the traffic it would produce.
147
  Although the 
court found these concerns valid, it held that the ordinance did not 
place restrictions on the hours or number of patients of a medical 
clinic and it would, therefore, be inappropriate to apply them to this 
zoning permit application.
148
 
While courts have found that zoning statutes cannot discrimi-
nate against methadone facilities, facility locations remain controver-
sial.  In Salem, Massachusetts, the zoning board rewrote its zoning 
ordinance to tighten its definition of “medical facility” and attempted 
to add language imposing additional restrictions on drug-dispensing 
facilities while leaving other medical offices unaffected all based on 
rumors of a pending methadone treatment facility application.
149
  Po-
tential and current neighbors of methadone facilities have raised ob-
jections to the location of treatment centers from Boise, Idaho,
150
 to 
Somers Point, New Jersey,
151
 to Columbia, Tennessee,
152
 voicing con-
cerns over crime rates, parking, traffic, and exposing children to ad-
dicts.
153
 
2. Physician and Dosage Requirements 
In addition to the facility restrictions, practitioners who wish to 
dispense methadone must meet special DEA registration require-
 
 145 Id. at 1289–90, 1292. 
 146 Id. at 1290. 
 147 Id. at 1291. 
 148 Id. at 1292. 
 149 Bella Travaglini, Salem Clinic Proposal Prompts Rewrite of Zoning Amendment, 
BOSTON.COM (June 29, 2010, 12:05 PM), http://www.boston.com/ 
yourtown/news/salem/2010/06/salem_ordinance.html. 
 150 Kiersten Throndsen, Methadone Clinic Has Some Upset Over Location, KBOI2.COM 
(Nov. 17, 2009, 10:55 PM), http://www.kboi2.com/news/70345467.html. 
 151 Shaun Smith, Narrow Street, Methadone Clinic Raise Safety Concerns for West Cedar 
Avenue, SHORE NEWS TODAY (Sept. 15, 2010), http://www.shorenewstoday.com/ 
index.php/mainland-/mainland/4305-narrow-street-methadone-clinic-raise-safety-
concerns-for-west-cedar-avenue.html. 
 152 Carley Gordon, Neighborhood Outraged over Proposed Clinic, WSMV (Oct. 27, 
2011, 3:19 PM), http://www.wsmv.com/story/15894787/neighborhood-outraged-
over-proposed-clinic.   
 153 See sources cited supra notes 149–52. 
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ments beyond those required for OxyContin,
154
 despite the fact that 
both are Schedule II controlled substances.  In addition to the nor-
mal registration requirements,
155
 a practitioner who wishes to dis-
pense methadone must obtain an additional, separate registration 
number from the DEA.
156
  The practitioner must also obtain the ap-
proval of and register with both the CSAT and the appropriate state 
methadone authority.
157
 
Methadone patients also face dosage and other types of re-
strictions that are much more severe than the ninety-day supply re-
striction on OxyContin, including limits on when patients can take 
methadone home and how much can be prescribed during the 
course of their treatment.
158
  A practitioner cannot prescribe more 
than thirty milligrams of methadone as an initial dose and more than 
forty milligrams on the first day of treatment, unless the practitioner 
documents that forty milligrams did not suppress withdrawal symp-
toms.
159
  A single take-home dose of methadone is permitted for the 
time when the methadone clinic is closed.
160
  In addition, the regula-
tions list criteria that help physicians evaluate patients for unsuper-
vised methadone use.
161
  If a patient meets the criteria, the regulations 
permit the patient to take a single dose per week outside the clinic 
during the first ninety days of treatment.
162
  During the second ninety 
days of treatment, the patient is permitted to take two doses per week 
for use outside the clinic.
163
  In the third ninety days, this quantity in-
creases to three doses per week.
164
  The patient is permitted a maxi-
mum supply of six take-home doses per week for the remainder of 
the first year of treatment.
165
  After the first year of continuous treat-
ment, the patient may receive a two-week supply at a time.
166
  After the 
second year of continuous treatment, the patient may reach the max-
 
 154 21 U.S.C. § 823(g)(1) (2006).   
 155 For a detailed discussion of the normal registration requirements, see supra 
Part II. 
 156 § 823(g)(1).   
 157 RANNAZZISI & CAVERLY, supra note 116, at 23.  
 158 42 C.F.R. § 8.12(h) (2011).   
 159 § 8.12(h)(3)(ii).   
 160 § 8.12(h)(4).   
 161 Id. 
 162 Id.    
 163 Id.    
 164 Id.    
 165 42 C.F.R. § 8.12(h)(4) (2011).      
 166 Id.    
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imum take-home amount—a one-month supply.
167
  The patient must 
continue to make monthly visits.
168
  If a patient requires an exception 
to the take-home structure, for example, because of employment, 
disability, or transportation hardships, the physician must submit to 
SAMHSA and (where applicable) to the state methadone authority 
an “exception request” for approval to deviate from these re-
strictions.
169
 
In sum, localities create targeted zoning restrictions that are dis-
criminatory and not based on empirical evidence to impede metha-
done facilities, governing agencies proffer no evidence of special 
skills or complexities in methadone treatment to substantiate addi-
tional physician registration requirements, and methadone dosage 
restrictions are draconian.  In contrast to the rigid regulatory struc-
ture for methadone, the OxyContin regulations do not require prac-
titioners to prescribe the medication from a federally-certified facility 
separate from their offices but does require them to comply with just 
one dosing limitation, which has an exception that permits a practi-
tioner to provide three prescriptions at once.
170
  In light of the simi-
larities between the chemical compositions of these two drugs, their 
incongruent treatment under the law seems unfounded.  Further-
more, in light of the increase in opiate prescription abuse, the regula-
tions appear to encourage the continued use of opiate pain medica-
tions while vigorously limiting access to methadone, which treats the 
very addiction that the OxyContin regulations facilitate. 
C. Buprenorphine 
Physicians in the United States have used low doses of bupren-
orphine since 1985 for the treatment of pain.
171
  In October 2002, the 
FDA approved two buprenorphine products containing high doses of 
the drug—Suboxone and Subutex—for the treatment of opiate ad-
diction.
172
  In its higher dosage, buprenorphine reduces craving, 
blocks the effect of heroin and other opiates, reduces adverse symp-
toms associated with withdrawal, and remains active for a longer du-
ration.
173
 
 
 167 Id.   
 168 Id.   
 169 42 C.F.R. § 8.11(h) (2011). 
 170 See supra Part III.A. 
 171 See DRUG ENFORCEMENT ADMIN., BUPRENORPHINE (2011), available at 
http://www.deadiversion.usdoj.gov/drugs_concern/buprenorphine.pdf.   
 172 Id.  
 173 Jones, supra note 19, at 4–5. 
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Following the recommendation of the Department of Health 
and Human Services, the DEA classified buprenorphine and the 
products containing the drug as Schedule III controlled substances.
174
  
Schedule III drugs have a lower potential for abuse than Schedule I 
or II drugs, have a currently accepted medical use, and abuse of these 
drugs “may lead to moderate or low physical dependence or high 
psychological dependence.”
175
 
Unlike methadone and similarly to OxyContin, practitioners can 
prescribe Suboxone and Subutex outside the heavily regulated OTP 
environment.
176
  Unlike OxyContin and similarly to methadone, how-
ever, to prescribe buprenorphine, practitioners must meet special 
registration criteria and the number of patients they can treat is lim-
ited.
177
  As with methadone, a practitioner who wishes to prescribe 
buprenorphine must obtain an additional registration with the DEA 
on an annual basis.
178
  Because buprenorphine is a Schedule III con-
trolled substance rather than a Schedule II controlled substance, 
however, the CSA permits practitioners to waive the additional regis-
tration requirement if they are able to meet certain criteria.
179
 
A practitioner who seeks waiver must first submit a written noti-
fication of intent to the Secretary of the DHHS.
180
  The written notifi-
cation must include the practitioner’s DEA registration number and 
a certification that the practitioner meets two of the following crite-
ria: is licensed under state law and (1) is board certified in addiction 
psychiatry from the American Board of Medical Specialties, or (2) has 
an addiction certification from the American Society of Addiction 
Medicine, or (3) is board certified in addiction medicine from the 
American Osteopathic Association, or (4) has other specialized train-
ing either through coursework or participation in clinical trials of the 
drug.
181
  The practitioner must also certify that he or she has the ca-
pacity to refer addiction treatment patients for other appropriate 
counseling and services and that he or she will not exceed the regu-
lated patient limits.
182
  Practitioners are limited to treating thirty pa-
 
 174 Id. at 4; see also 21 U.S.C. § 812(c) shed. III (2006).  
 175 § 812(b)(3)(A)–(C). 
 176 PHYSICIANS & LAWYERS FOR NAT’L DRUG POLICY, supra note 12, at 41. 
 177 See id. 
 178 See 21 U.S.C. § 823(g)(2) (2006). 
 179 Id.  
 180 § 823(g)(2)(B)–(D). 
 181 §§ 823(g)(2)(B)(i), 823(g)(2)(G)(ii). 
 182 § 823(g)(2)(B)(ii).  
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tients in the first year, with a maximum of one hundred patients 
thereafter.
183
 
The CSAT then evaluates whether the practitioner meets the 
waiver requirements.  If so, the CSAT refers the waiver request to the 
DEA.
184
  If the DEA approves the practitioner’s request, the practi-
tioner receives a Unique Identification Number.
185
  At this time, the 
practitioner may dispense buprenorphine.
186
  Over a two-year period, 
the practitioner must meet stringent record-keeping requirements, 
including keeping records of receipt, storage, and distribution,
187
 
none of which are required to dispense OxyContin.
188
 
Practitioners may dispense Schedule III controlled substances 
with a written or oral prescription.
189
  In contrast to every other 
Schedule III medication, only physicians can prescribe buprenor-
phine.
190
  The physician must include his or her regular DEA registra-
tion number and Unique Identification Number on each prescrip-
tion.
191
  The physician must also maintain a record of each 
prescription for a period of at least two years.
192
  As of June 2009, the 
SAMHSA and the DEA had approved nearly 15,700 physicians to pro-
vide office-based buprenorphine treatment, about 13,150 to treat up 
to thirty patients, and about 2500 to treat up to one hundred pa-
tients.
193
 
The rules provide for an exception to the registration or regis-
tration waiver requirement to permit a practitioner to administer, but 
not prescribe, buprenorphine in an emergency situation in which a 
patient is experiencing acute withdrawal symptoms and in which it 
would be impractical to require a practitioner to meet the registra-
tion requirement.
194
  Under the so-called “three-day rule,” a practi-
tioner may administer three daily doses of the medication to last for a 
single seventy-two-hour period, permitting the practitioner a period 
 
 183 § 823(g)(2)(B)(iii).   
 184 RANNAZZISI & CAVERLY, supra note 116, at 23. 
 185 Id. 
 186 Id. 
 187 Id. 
 188 See supra Part III.A. 
 189 21 U.S.C. § 829(b) (2006). 
 190 Robert J. Roose et al., Nurse Practitioner and Physician Assistant Interest in Prescrib-
ing Buprenorphine, 34 J. SUBSTANCE ABUSE TREATMENT 456, 458 (2008). 
 191 21 C.F.R. § 1306.05(a)–(b) (2011). 
 192 § 1304.04(a). 
 193 DRUG ENFORCEMENT ADMIN., supra note 171. 
 194 21 C.F.R. § 1306.07(b) (2012). 
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to arrange for the patient’s treatment in a detoxification
195
 or 
maintenance program.
196
  The practitioner may not renew or extend 
the seventy-two hour period.
197
 
In sum, addiction-assistance medications’ regulations require 
special DEA registration, and practitioner training and impose facility 
restrictions, dosage limits, and patient limits.  These restrictions stand 
in stark contrast to the controls imposed on OxyContin—a drug that 
is abused and classified in a schedule above buprenorphine, yet is 
limited only through a quota that has steadily increased over an eight-
year period and through restrictions on prescription refills. 
IV.  RECOMMENDED REFORMS 
The results of the SAMHSA 2009 annual survey on national drug 
use highlight two reforms that are required to address OxyContin 
abuse—proper medication disposal and physician oversight and/or 
training.
198
  The survey breaks down the reported sources of prescrip-
tion pain relievers based on the users’ most recent non-medical uses 
and found that 70.2% of users obtained the drug from a friend or 
relative, 17.6% obtained the drug from one doctor, 4.8% obtained 
the drug from a drug dealer or stranger, and 0.4% bought the drug 
on the Internet.
199
  Additionally, eighty percent of the friends or rela-
tives who provided the drug to the users obtained the drug from just 
one doctor.
200
  These statistics highlight two issues on the supply side 
of this equation: (1) the need to appropriately advise patients on how 
to dispose of their medications; and (2) the need for heightened re-
quirements on practitioners who prescribe opiate pain medications. 
 
 195 See 21 U.S.C. § 802(30) (2006) (“The term ‘detoxification treatment’ means 
the dispensing, for a period not in excess of one hundred and eighty days, of a nar-
cotic drug in decreasing doses to an individual in order to alleviate adverse physio-
logical or psychological effects incident to withdrawal from the continuous or sus-
tained use of a narcotic drug and as a method of bringing the individual to a narcotic 
drug-free state within such period.”). 
 196 Questions & Answers, DRUG ENFORCEMENT ADMIN., http:// 
www.deadiversion.usdoj.gov/drugreg/faq.htm (last visited, Feb. 17, 2012). 
 197 Id.  
 198 See U.S. DEP’T OF HEALTH & HUMAN SERVS., PUB. NO. SMA 10-4586, RESULTS 
FROM THE 2009 NATIONAL SURVEY ON DRUG USE AND HEALTH: VOLUME I. SUMMARY OF 
NATIONAL FINDINGS 28 (2010), available at http://www.oas.samhsa.gov/ 
NSDUH/2k9NSDUH/2k9ResultsP.pdf. 
 199 Id. 
 200 Id. 
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A. OxyContin Supply Reforms 
1. Disposal 
The OxyContin REMS provides that prescribing physicians 
should advise patients to flush unused tablets down the toilet.
201
  As 
noted earlier in this Comment, the REMS is not binding on a physi-
cian and is not used to police physician or patient practices.
202
  The 
REMS should be updated to impose more stringent labeling re-
quirements, particularly advising patients of the appropriate disposal 
method for unused pills.  Currently, the appropriate disposal method 
is contained in an eight-page medication guide provided to 
OxyContin patients.
203
  The disposal instructions should not be bur-
ied in such a long, dense document, but rather should be prominent-
ly placed on the label.  There are, however, many concerns about 
contamination of the water supply with prescription medications.
204
  
Therefore, patients should be encouraged to also use drug take-back 
programs to dispose of unused OxyContin. 
On October 12, 2010, President Obama signed the Secure and 
Responsible Drug Disposal Act into law.
205
  The Act amends the CSA 
to extend to states and private entities the ability to create drug take-
back programs, which could provide an additional outlet for the safe 
disposal of old or unwanted medication.
206
  Prior to this law, only law 
enforcement authorities could lawfully collect controlled substanc-
es.
207
  On September 25, 2010, the DEA conducted a nationwide drug 
take-back day, collecting more than 121 tons of medicine at over 
4,000 collection sites.
208
  The new law will permit exploration of these 
programs.
209
  Perhaps doctors’ offices, hospitals, and pharmacies 
should also have a receptacle for medication disposal, which would 
 
 201 PURDUE PHARMA, supra note 92, at 33. 
 202 Id. 
 203 PURDUE PHARMA, supra note 96. 
 204 See MAE WU ET. AL., DOSED WITHOUT PRESCRIPTION: PREVENTING 
PHARMACEUTICAL CONTAMINATION OF OUR NATION’S DRINKING WATER 3 (2009),  avail-
able at http://docs.nrdc.org/health/files/hea_10012001a.pdf. 
 205 Pub. L. No. 111-273, 124 Stat. 2858 (2010). 
 206 Carol M. Ostrom & Lauren C. Williams, New State Pain-Medication Law Has Doc-
tors and Patients Nervous, SEATTLE TIMES (Sept. 11, 2010, 12:04 PM), 
http://seattletimes.nwsource.com/html/localnews/2012873602_drugs12m.html. 
 207 Id. 
 208 Alicia A. Caldwell, DEA Drug Take-Back Nets 121 Tons of Unwanted Drugs, 
ASSOCIATED PRESS, Oct. 5, 2010, available at 
http://www.msnbc.msn.com/id/39526659/ns/health-more_health_news/. 
 209 See H.B. 1121, 2011 Leg., 1st Reg. Sess. (Ind. 2011). 
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enable a patient to access a proper disposal location without substan-
tially deviating from his or her normal routine or waiting for a drug 
take-back program day.
210
  New Jersey is also exploring secure recep-
tacles, such as refurbished, locked mailboxes at municipal police sta-
tions.
211
 
2. Physician Training 
The legal treatment of methadone and buprenorphine empha-
sizes the importance of practitioner training for the proper dispens-
ing of these drugs.  OxyContin prescribers should be required to 
meet similar training standards.  The OxyContin REMS is insufficient 
to ensure that practitioners are properly trained.  Although infor-
mation that the manufacturer provides to practitioners contains use-
ful guidelines, there is no requirement that practitioners follow the 
guidelines, or even read the materials before prescribing the medica-
tion.
212
  At a minimum, practitioners should have to return the certifi-
cation form currently enclosed in the REMS materials to be eligible 
to prescribe OxyContin.  Perhaps a DEA registration-and-waiver 
structure similar to that applicable to buprenorphine should also ap-
ply to OxyContin.  This would allow practitioners with particularized 
training in pain management to prescribe OxyContin, and encourage 
pain-management patients to pursue care with a practitioner with ex-
pertise in relieving pain.  This system may help ensure that legitimate 
pain sufferers access appropriate care from physicians who meet par-
ticularized training requirements.  Furthermore, it may be easier for 
practitioners who deal with pain patients on a regular basis to differ-
entiate the illegitimate users from the legitimate users. 
Finally, health insurers, both private and public, should refuse to 
cover prescriptions of OxyContin for ailments other than chronic or 
long-term pain.  OxyContin was specifically designed to treat patients 
with around-the-clock moderate-to-severe pain.
213
  Accordingly, doc-
tors should not treat patients suffering from short-term conditions 
that require pain suppressing medications with OxyContin. 
 
 210 See Bill Would Let Indiana Pharmacies Collect Old Meds, ASSOCIATED PRESS, Jan. 10, 
2011, available at http://www.ibj.com/bill-would-let-indiana-pharmacies-collect-old-
meds/PARAMS/article/24511. 
 211 S. 541, 214th Leg., 2010 Sess. (N.J. 2010). 
 212 See PURDUE PHARMA, supra note 92, at 35(noting that the completion of the Ed-
ucation Confirmation Form does not affect a practitioner’s ability to prescribe 
OxyContin). 
 213 OxyContin—Questions and Answers, supra note 3. 
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3. State Legislatures and the Washington State Model 
State legislatures should act to limit the prescribing of 
OxyContin to patients in chronic or long-term pain, for which the 
drug is designed.  Washington state’s efforts represent one example 
of such an initiative.  At the beginning of 2010, the Washington State 
Legislature introduced, and quickly passed, a bill aimed at curbing 
the disparate legal treatment of pain relief medications.
214
  Statistics 
finding that more Washington residents died from prescription over-
doses than car accidents prompted quick action.
215
  Governor Chris-
tine Gregoire signed the bill into law on March 25, 2010; it became 
effective on June 10, 2010.
216
 
The first of its kind in the nation, the law requires the state’s ap-
propriate rulemaking agencies to determine a painmedication dos-
age level at which practitioners would need to refer patients to pain 
specialists.
217
  Although the law does not create specific penalties for 
failing to adhere to the forthcoming rules, state officials have repre-
sented a practitioner who violates the rules will face sanctions from 
the state licensing boards that could include losing the right to prac-
tice medicine.
218
  The state adopted voluntary guidelines for practi-
tioners three years ago, but a 2009 survey found that about half of 
doctors were unaware of them and many were simply not following 
them.
219
  To strike a balance between facilitating pain relief and creat-
ing addiction controls, the law exempts patients with cancer, acute 
injury or surgery, or who are in end-of-life care from the new re-
strictions.
220
 More states should consider initiatives like Washington’s 
and attempt to balance access to pain medication while minimizing 
the diversion of pain medication for illicit uses. 
 
B. Reforming the Demand for Addiction-Assistance Medications 
 
In addition to the reforms on the supply side of the issue, re-
forms must also address the demand side by providing addicts the 
 
 214 WASH. REV. CODE § 18.32.785 (2010). 
 215 Ostrom & Williams, supra note 206. 
 216 H.R. 2876, 61st .Leg., Reg. Sess. (Wa. 2010). 
 217 WASH. REV. CODE § 18.32.785 (2010). 
 218 Barry Meier, Move to Restrict Pain Killers Puts Onus on Doctors, N.Y. TIMES, July 29, 
2010, at B1. 
 219 Id. 
 220 Ostrom & Williams, supra note 206. 
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opportunity to obtain medication to treat their disease.  According to 
post-marketing surveillance by buprenorphine’s manufacturer, fifty 
percent of physicians who are eligible to treat patients with bupren-
orphine reported that patients who are waiting to get into treatment 
utilize diverted buprenorphine to treat themselves. 
221
  The surveyed 
physicians attributed this fact to the insufficient number of physicians 
who are eligible to prescribe buprenorphine and to the fact that 
those physicians are not evenly distributed throughout the country.
222
  
Accordingly, the patient limit should be eliminated.
223
  The patient 
limitations were designed to prevent hundreds of patients from wait-
ing outside doctors’ offices for treatment.
224
  Despite patient demand 
that outweighs resources, methadone facilities do not suffer from 
such a problem.
225
  Therefore, it seems overly precautionary to limit 
the number of buprenorphine patients.  Additionally, practitioners 
prescribing buprenorphine need to first demonstrate their training 
in the treatment of addiction or obtain a special DEA registration.
226
  
A physician who chooses to develop expertise in this area should be 
allowed to treat as many patients as he or she is capable of treating.  
Just as pain-management patients deserve access to their medications 
and should consult practitioners with expertise in their ailment, so 
too should addicts.  Furthermore, nurse practitioners and physician 
assistants should be able to prescribe buprenorphine.
227
  The policy 
reason for restricting nurse practitioners and physician assistants 
from prescribing buprenorphine is unclear in light of the fact that 
they can prescribe other Schedule III drugs.
228
  As the role of non-
physician providers has dramatically increased in the last decade, this 
unexplained restriction may further unnecessarily limit access to bu-
prenorphine.
229
 
With regard to methadone, despite findings that demonstrate 
the effectiveness of maintenance treatment, less than twenty percent 
 
 221 Off-Label Use of Buprenorphine for Pain Worries Officials, ALCOHOLISM & DRUG 
ABUSE WKLY., Jan. 11, 2010, at 2. 
 222 Id. 
 223 For a discussion of patient limits, see supra notes 182–83. 
 224 Laurie Barclay, New Legislation Increases Number of Patients Allowed for Treatment 
with Buprenorphine, MEDSCAPE MED. NEWS (Dec. 20, 2006), http:// 
www.medscape.com/viewarticle/549706. 
 225 See Ruth Schubert, Wait for Methadone Puts Hundreds of Lives on Hold, SEATTLE 
POST-INTELLIGENCER, Mar. 17, 2003, at A1.  
 226 See supra text accompanying notes 178–82. 
 227 See Roose, supra note 190, at 458. 
 228 Id. at 456. 
 229 Id. at 456, 459. 
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of the heroin addicts in the United States use the treatment.
230
  Hero-
in addicts who use maintenance treatment decrease their weekly her-
oin intake by sixty-nine percent, their criminal activity by fifty-two 
percent, and increase their full-time employment by twenty-four per-
cent.
231
  Therefore, the legal structure for methadone should reflect 
its positive effects, encouraging use and increasing the availability of 
this treatment.  Instead, because addicts can only receive this treat-
ment at stand-alone facilities, which are often the subject of local con-
troversy, clinic locations and hours of operation can be inconvenient, 
and addicts using the facility may be subject to the negative reactions 
by the surrounding community.
232
  This “can create powerful feelings 
of mistrust and alienation and a strong reluctance to seek out or par-
ticipate in programs.”
233
  Furthermore, two states, North Dakota and 
Wyoming, simply do not have methadone treatment facilities.
234
  The 
number of facilities in other states varies from one, in Mississippi, to 
almost 150, in New York and California respectively.
235
  Additional 
barriers to access include fees, forms to fill out, referral requirements, 
and waiting lists.
236
  The law should reflect methadone’s positive ef-
fects rather than discourage physicians and addicts from using it in 
addiction recovery. 
V. CONCLUSION 
The legal structure for OxyContin enables a patient to obtain his 
or her drug of choice with relative ease because the patient can ob-
tain it through any practitioner at any healthcare facility.  But, should 
that patient become addicted to OxyContin, he or she will have to 
find a practitioner and/or facility that has jumped through several 
regulatory hoops to have the power to prescribe a drug to help him 
or her combat this addiction. 
 
 230 Robert Mathias, NIH Panel Calls for Expanded Methadone Treatment for Heroin Ad-
diction, NAT’L INST. DRUG ABUSE NOTES (Nov./Dec. 1997), 
http://archives.drugabuse.gov/NIDA_Notes/NNVol12N6/NIHPanel.html. 
 231 Id. 
 232 See CTRS. FOR DISEASE CONTROL AND PREVENTION, SUBSTANCE ABUSE TREATMENT 
FOR INJECTION DRUG USERS: A STRATEGY WITH MANY BENEFITS 3 (2002), available at 
http://www.cdc.gov/idu/facts/TreatmentFin.pdf. 
 233 Id. 
 234 See Opioid Treatment Program Directory, SUBSTANCE ABUSE & MENTAL HEALTH 
SERVS. ADMIN., http://dpt2.samhsa.gov/treatment/directory.aspx (last visisted, Jan. 
27, 2012) (select “North Dakota” and “Wyoming from” drop down menu). 
 235 Id.  To view the statistics for each state, select “Mississippi”,  “New York”, and 
“California” from the drop down menu. 
 236 CTRS. FOR DISEASE CONTROL AND PREVENTION, supra note 232. 
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Drug addicts are not a beloved part of society.
237
  One need not 
search beyond the transcripts from zoning board hearings or news-
paper articles regarding methadone clinics to appreciate this.
238
  The 
courts have played a role in protecting addicts from discrimination by 
invalidating discriminatory zoning actions, but only Congress and the 
relevant state and federal agencies can change a legal structure for 
medications that discriminates against addicts.  This structure has 
created a recipe for abusing OxyContin by failing to ensure that phy-
sicians are properly trained to dispense OxyContin and by failing to 
educate the public on how to properly dispose of pain medications.  
But paradoxically, this structure also seems to punish addicts by deny-
ing them access to medications proven to assist them in combating 
their addiction. 
A fear that addicts will abuse drugs, even those designed to help 
them, may explain the more stringent regulation of methadone and 
buprenorphine.  But OxyContin is abused every day.  The drug’s time 
release properties, the amount of oxycodone contained in the pills, 
and the ease with which the pills can be tampered creates a perfect 
storm for abuse.  The legal structure for OxyContin should reflect 
this, and the disparities between the regulations for addiction-
assistance medications and OxyContin should be rectified through 
the creation of more stringent prescription guidelines, better disposal 
instructions, and increased physician training. 
 
 
 237 See Americans Want Insurance to Cover Addiction; Unsure if it Does, HAZELDON 
FOUND. (Feb. 3, 2009), http://www.hazelden.org/web/public/pr090209 
healthinsurance.page. 
Although 78 percent of Americans recognize that addiction is a chron-
ic disease rather than a moral failing, the words used by those surveyed 
when asked to describe people who have problems with drugs or alco-
hol included: “sinner,” “irresponsible,” “selfish,” “stupid,” “uncaring,” 
“loser,” “undisciplined,” “pitiful,” “pathetic,” “weak,” “criminal,” “dere-
lict,” “washed up” and “crazy.”  The single highest negative conse-
quence reported of having a family member with a drug problem was 
“embarrassment/social stigma.”  
Id. 
 238 See supra note 140, 149–52 and accompanying text.  
